Abstract

HIV-1 transactivator protein (Tat) induces tight junction (TJ) dysfunction and amyloid-beta (Aβ) clearance dysfunction, contributing to the development and progression of HIV-1-associated neurocognitive disorder (HAND). The Rho/ROCK signaling pathway has protective effects on neurodegenerative disease. However, the underlying mechanisms of whether Rho/ROCK protects against HIV-1 Tat-caused dysfunction of TJ and neprilysin (NEP)/Aβ transfer receptor expression have not been elucidated. C57BL/6 mice were administered sterile saline (i.p., 100 μL) or Rho-kinase inhibitor hydroxyfasudil (HF) (i.p., 10 mg/kg) or HIV-1 Tat (i.v., 100 μg/kg) or HF 30 min before being exposed to HIV-1 Tat once a day for seven consecutive days. Evans Blue (EB) leakage was detected via spectrophotometer and brain slides in mouse brains. The protein and mRNA levels of zonula occludens-1 (ZO-1), occludin, NEP, receptor for advanced glycation end products (RAGE), and low-density lipoprotein receptor-related protein 1 (LRP1) in mouse brain microvessels were, respectively, analyzed by Western blotting and quantitative real-time polymerase chain reaction (qRT-PCR) analyses. Exposure of the mice to HIV-1 Tat increased the amount of EB leakage, EB fluorescence intensity, blood–brain barrier (BBB) permeability, as well as the RAGE protein and mRNA levels, and decreased the protein and mRNA levels of ZO-1, occludin, NEP, and LRP1 in mouse brain microvessels. However, these effects were weakened by Rho-kinase inhibitor HF. Taken together, these results provide information that the Rho/ROCK signaling pathway is involved in HIV-1 Tat-induced dysfunction of TJ and NEP/Aβ transfer receptor expression in the C57BL/6 mouse brain. These findings shed some light on potentiality of inhibiting Rho/Rock signaling pathway in handling HAND.

Highlights

  • Active antiretroviral therapy (HAART) is not capable of eradicating human immunodeficiency virus (HIV) infection in the central nervous system (CNS), it succeeds in reducing viral loads in the blood to an undetectable level [1]

  • To assess the permeability of blood–brain barrier (BBB), Evans Blue (EB) leakage and EB fluorescence intensity were examined by spectrophotometry and fluorescence microscopy, respectively, and the zonula occludens-1 (ZO-1) expression in mouse brain microvessels was assessed with Western blotting

  • HIV-1 transactivator protein (Tat) at 100 μg/kg body weight significantly increased EB leakage and EB fluorescence intensity compared to the control group (***P < 0.001) and reduced the expression of Zonula occludens (ZO)-1 compared to the control group(**P < 0.01)

Read more

Summary

Introduction

Active antiretroviral therapy (HAART) is not capable of eradicating human immunodeficiency virus (HIV) infection in the central nervous system (CNS), it succeeds in reducing viral loads in the blood to an undetectable level [1]. (HIV-1)-infected individuals receiving successful HAART suffer some level of HIV-1-associated neurocognitive disorder (HAND). The mechanisms of HIV infection causing neurocognitive impairment aren’t elucidated completely. It has been shown that several mechanisms of vascular pathology caused by HIV-1 can be reproduced by the administration of the HIV-1 transactivator protein (Tat), which is made by HIV-1-infected cells [5]. HIV-1 Tat shows harmful effects on the development and progression of HAND. HIV-1 Tat is an inflammatory factor with neuroexcitability and neurotoxicity [6]; it can facilitate amyloid-beta (Aβ) accumulation

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call